PT-141 vs Melanotan II: Two Melanocortin Agonists, Very Different Safety Stories

PT-141 is a cyclic seven-amino-acid peptide with relative MC3R/MC4R selectivity. Early clinical work explored bremelanotide as a therapy for sexual dysfunction, and the molecule was approved by the FDA in 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women — a centrally acting, on-demand subcutaneous injection.^[1][2][3]

Crucially, Vyleesi's FDA label is for premenopausal women with acquired, generalised HSDD — not a general 'libido enhancer' for any user. The peptide-as-Vyleesi pathway is a prescription medicine with a defined indication, screening, and contraindication list. Common adverse events documented in trials include nausea, flushing, transient blood-pressure changes, and skin pigmentation changes, particularly in patients with darker skin.^[2][1]

PT-141 sold outside that prescription pathway — as research-peptide vials marketed for 'arousal' — does not carry the FDA-label safety screening that Vyleesi provides. The mechanism is the same; the regulatory frame is not.^[2]

Melanotan II is a non-selective melanocortin agonist active across MC1R-MC5R. It was originally developed as a research tool for skin-pigmentation pathways through MC1R activation on melanocytes. It is not authorised by the EMA, the FDA, the UK MHRA, the Australian TGA, or other major regulators as a medicine or a consumer product in any indication.^[8][7][6]

The UK Medicines and Healthcare products Regulatory Agency has issued explicit public warnings stating that melanotan injections could pose a serious risk to health and that selling them in the UK is illegal. The Australian Therapeutic Goods Administration has issued comparable warnings, including specifically calling out non-approved use and the absence of any quality or safety assurance behind unregulated supply.^[7][6]

Published case-series and review work in dermatology has connected Melanotan II use with adverse events ranging from gastrointestinal effects and hyperpigmentation through to documented cases of eruptive melanocytic nevi and melanoma diagnosed after use. The causal interpretation of any single case is debated, but the pattern is the reason regulators treat unregulated Melanotan II as a public-health concern.^[4][5]

The table below summarises what published literature and regulatory documents describe for each peptide. Use it as a research and safety map, not as a dosing or self-administration guide.^[3][8][2][7]

| Attribute | PT-141 (bremelanotide) | Melanotan II | | --- | --- | --- | | Class | Cyclic heptapeptide melanocortin agonist | Linear non-selective melanocortin agonist | | Receptor selectivity | Relative MC3R/MC4R selectivity | Non-selective: MC1R, MC2R, MC3R, MC4R, MC5R | | Research focus | Central sexual-arousal pathways, HSDD | Skin pigmentation via MC1R-melanocyte activation | | Regulatory status | FDA-approved as Vyleesi (2019) for premenopausal HSDD | No EMA, FDA, MHRA, or TGA authorisation in any indication | | Documented safety concerns | Nausea, flushing, transient blood-pressure changes, focal pigmentation, contraindications per Vyleesi label | Mole/nevus changes, eruptive nevi, melanoma case reports, GI effects, hyperpigmentation, unregulated supply quality | | EU consumer availability | Prescription medicine Vyleesi is not separately EMA-authorised; bremelanotide does not have an EMA EPAR | Unregulated injectable; explicit MHRA and TGA warnings against sale and use | | Honest framing | A real medicine with a defined indication, not a generic arousal supplement | A research tool repurposed as a tanning shortcut without medical authorisation or quality assurance |^{[3][2][4][5][7][6]}

Read the table as a structural comparison of two melanocortin agonists with very different research, indication, and safety stories — not as a label that tells any reader whether either peptide is right for them.

Both PT-141 and Melanotan II act on the central melanocortin system. The bremelanotide (Vyleesi) clinical trials describe transient blood-pressure increases, nausea (which was the most common adverse event), flushing, and focal hyperpigmentation as adverse events — the kind of profile that is managed in a prescriber-supervised, on-demand, label-restricted setting and is built into the FDA approval and contraindication list.^[2][1]

Melanotan II's safety picture is more concerning. Published case reports and reviews describe nausea, hyperpigmentation, eruptive melanocytic nevi, and instances of melanoma diagnosed in patients with prior unregulated Melanotan II use. The causal mechanism debate continues, but the dermatology pattern — pigmented lesion changes after non-selective MC1R activation — is exactly why the UK MHRA and Australian TGA have issued public warnings.^[4][5][7][6]

Add the layer of unregulated supply: Melanotan II is typically sold without batch-specific Certificate of Analysis, identity confirmation, or any chain-of-custody quality system. That is a separate dimension of harm — beyond pharmacology, the buyer does not know what is in the vial.^[7]

Peptyds publishes PT-141 in the research-peptide category alongside transparent regulatory framing: the FDA-approved indication for bremelanotide is HSDD in premenopausal women, the molecule is supplied via prescription as Vyleesi, and research-peptide PT-141 does not replace that pathway.^[2][3]

Peptyds publishes Melanotan II with explicit safety-first framing: non-selective MC1R-MC5R activity, dermatology case literature on pigmented-lesion changes, and the MHRA / TGA public warnings against use. The product page exists because some research customers want material with quality documentation, not because Peptyds endorses cosmetic tanning use.^[4][5][7][6]

Anyone considering personal use of either peptide should consult a qualified healthcare professional, and anyone with changing pigmented skin lesions should see a dermatologist regardless of peptide history.